rss
Br J Ophthalmol 2009;93:1353-1358 doi:10.1136/bjo.2008.141879
  • Original Article
  • Clinical science

Predictive factors of visual and anatomical outcome after intravitreal bevacizumab treatment of neovascular age-related macular degeneration: an optical coherence tomography study

  1. R P Singh1,
  2. E X Fu1,
  3. S D Smith1,
  4. D R Williams1,2,
  5. P K Kaiser1,2
  1. 1
    Cole Eye Institute, Cleveland, Ohio, USA
  2. 2
    Digital OCT Reading Center, Cleveland, Ohio, USA
  1. Correspondence to Dr P K Kaiser, Digital OCT Reading Center, Cole Eye Institute, Cleveland Clinic, 9500 Euclid Ave, Desk i3, Cleveland, OH 44195, USA; pkkaiser{at}aol.com
  • Accepted 7 May 2009
  • Published Online First 24 June 2009

Abstract

Aim: To evaluate the baseline visual and optical coherence tomography (OCT) factors on outcomes after intravitreal bevacizumab treatment of subfoveal neovascular age-related macular degeneration (AMD).

Methods: A retrospective analysis of 73 eyes treated with intravitreal bevacizumab for subfoveal neovascular AMD was performed. Change in best corrected Snellen visual acuity (BCVA) and central retinal thickness (CRT) on OCT were the primary outcomes. Automated and manual measurements were made for all OCT characteristics.

Results: Seventy-three (100%) and 58 (79.5%) eyes were followed for 3 and 6 months, respectively. The mean BCVA improved from 20/177 to 20/160 (p = 0.03) at 3 months and to 20/143 (p = 0.04) at 6 months. The mean CRT decreased 93 µm (p<0.0001) and 105 µm (p<0.0001) at 3 and 6 months, respectively. Baseline BCVA worse than 20/100 was associated with greater visual improvement (p≤0.04). Eyes with baseline CRT greater than 400 µm experienced a greater mean CRT reduction (p<0.05). Treatment-naïve patients had a greater mean CRT reduction than those previously treated with any modality (p<0.05)

Conclusions: Baseline BCVA and CRT positively influence mean visual and CRT improvement, respectively, after intravitreal bevacizumab in wet AMD. Any prior treatment predicted less CRT reduction.

Footnotes

  • Competing interests None.

  • Provenance and Peer review Not commissioned; externally peer reviewed.

  • Ethics approval Ethics approval was provided by Cleveland Clinic Institutional Review Board.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All versions of this article:
    1. bjo.2008.141879v1
    2. 93/10/1353 most recent

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.